Evidence map›Paper›PMID 40017673›Full record

ArticlePathology oncology research : POR2025

A novel automated IHC staining system for quality control application in ALK immunohistochemistry testing.

Chunxiao Hou, Xueru Song, Hongwei Chen, Chengdong Chang, Jinfeng Lu, Cheng Li, Haiyan Qu, Rui Guo, Jingyi Xu, Liming Xu

Abstract read
In one paragraph

Article in Pathology oncology research : POR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chunxiao HouDepartment of Pathology, Haining People's Hospital, Haining, Zhejiang, China.
Xueru SongDepartment of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Hongwei ChenDepartment of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Chengdong ChangDepartment of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jinfeng LuHangzhou Bailing Biotechnology Co., Ltd., Hangzhou, China.
Cheng LiHangzhou Bailing Biotechnology Co., Ltd., Hangzhou, China.
Haiyan QuHangzhou Bailing Biotechnology Co., Ltd., Hangzhou, China.
Rui GuoHangzhou Bailing Biotechnology Co., Ltd., Hangzhou, China.
Jingyi XuHangzhou Bailing Biotechnology Co., Ltd., Hangzhou, China.
Liming XuDepartment of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The establishment of positive and negative controls in immunohistochemistry (IHC) screening for anaplastic lymphoma kinase (ALK) rearrangements is essential in the treatment of lung adenocarcinoma. However, positive control of patient tissue is rare and comes with ethical issues. A novel automated solution for ALK IHC quality control management was investigated by comparison with the established D5F3 antibody on the VENTANA system in 87 lung adenocarcinoma specimens with known ALK status re-analyzed by fluorescence

Indexed as

AdenocarcinomaBiomarkers, TumorImmunohistochemistryLung NeoplasmsReceptor Protein-Tyrosine KinasesAdenocarcinoma of LungAnaplastic Lymphoma KinaseHumansIn Situ Hybridization, FluorescenceQuality ControlALK protein, humanAnaplastic Lymphoma KinaseBiomarkers, TumorReceptor Protein-Tyrosine Kinasesanaplastic lymphoma kinase gene ALKautomatedcontrols in liquid form (CLFs)lung adenocarcinomaquality controlrabbit monoclonal antibody

Identifiers

PMID40017673
PMCPMC11864879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.